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A best evidence topic in upper gastrointestinal surgery was written according to a structured protocol.
The question addressed was whether neoadjuvant chemotherapy (CT) or chemoradiotherapy (CRT) in
patients with resectable oesophageal cancer is associated with the best clinical outcome. 1115 papers
were found of which 5 papers were identiﬁed to answer the clinical question including 2 randomised
controlled trials (level II), 2 prospective series (level II) and one retrospective study (level III). The evi-
dence suggests CRT signiﬁcantly increases the pathological complete response rate and in some studies
this is associated with a signiﬁcant survival advantage. This is at the cost of an increase in peri-operative
morbidity and mortality. However, both randomised studies were signiﬁcantly underpowered and no
standard CT or CRT regimen appears to have been used in any study. Therefore, controversy still exists as
to whether neoadjuvant CT or CRT is more beneﬁcial and this has lead to variation in practice around the
globe. Two randomised controlled trials are currently underway which will hopefully answer this
important clinical question.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Based on the clinical scenario presented below, a search was
constructed according to a structured protocol as described in a
recent ‘best evidence’ paper in the International Journal of Surgery.1
Best BETs are designed to answer clinically relevant questions and
allow clinicians to rapidly review the literature on a deﬁned topic.
Although a meta-analysis comparing neoadjuvant chemotherapy
(CT) and chemoradiotherapy (CRT) has been conducted in oeso-
phageal cancer,2 it only included randomised studies and assessed
the impact of post-operative mortality and survival only. Here we
review all the pertinent literature which directly compares CT with
CRT and assess other important clinical factors, such as toxicity and
the differences in pathological complete response rate and margin
status.
2. Clinical scenario
You are in the outpatient clinic with a 75-year-old male patient
who has recently been diagnosed with oesophageal cancer. HisHospitals Birmingham NHS
ton, B15 2WB Birmingham,
(0) 161 3715996.
amilton), ewen.grifﬁths@uhb.
ciates Ltd. Published by Elsevier Ltcomputed tomogram, positron emission tomography (PET) and
endoscopic ultrasound show a potentially resectable distal adeno-
carcinoma (T3, N1, M0). His general health is good and he is suitable
for neoadjuvant therapy followed by oesophagectomy. He has been
reading about the oncological options on the internet and asks
whether he will be receiving neoadjuvant CT or neoadjuvant CRT
prior to his surgery. You decide to check the recent literature to
determinewhich neoadjuvant therapy prior to oesophagectomy for
cancer offers the best clinical outcomes: CRT or CT?
3. Three-part question
In patients undergoing neoadjuvant treatment prior to oeso-
phagectomy, does neoadjuvant CT or neoadjuvant CRT improve
outcomes?
4. Search strategy
A Medline search from 1946 to 2013 using the Ovid interface for
the terms: (oesophagectomy [All Fields] OR oesophageal neoplasia
[All ﬁelds]) AND (neoadjuvant therapy [All Fields] OR neoadjuvant
chemotherapy OR neoadjuvant chemoradiotherapy OR pre-
operative chemotherapy OR pre-operative chemoradiotherapy)
was performed. Results were limited to papers published in the
English language and those relating to Humans. Only papers whichd. All rights reserved.
Table 1
Best evidence papers.
Author, date
and country
Patient group Study type (level of
evidence)
Regimen Key outcomes Comments
Stahl, 2009,
Germany2
119 patients with cT3e4NxM0
AC of lower oesophagus or
gastric cardia
CT (n ¼ 59)
CRT (n ¼ 60)
Unblinded, prospectively
randomised phase III
trial (II)
CT: 15 weeks (w) of cisplatin, ﬂuorouracil
(5-FU) þ leucovorin
CRT: same CT for 12 w followed by 3 w
30 Gy RT in 15 fractions þ cisplatin þ
etoposide
OS: 21.1 months CT, 33.1 months CRT.
3 year survival 27.7% for CT, 47.4%
after CRT (p ¼ 0.07)
Toxicity: No difference
Path CR: 15.6% after CRT, 2% after CT
(p ¼ 0.03)
Hospital Mortality: 3.8% after CT and
10% after CRT (p ¼ 0.26)
3 year DFS: 59.0% for CT vs. 76.5% for CRT
(p ¼ 0.06)
Aimed for 354 patients but ﬁnished
prematurely due to low accrual. Power
to detect a 10% difference only 40%.
52 in CT and 49 pts in CRT group
underwent surgery. Reasons for no
surgery were toxicity chemo (2 vs. 2),
tumour progression (3 v 5), unﬁt
(0 v 1) and other (2 v 3), for CT vs.
CRT groups respectively. Complete
resection was 69.5% in CT group vs.
72% for CRT group.
Median follow-up 45.6 months.
Low dose of radiotherapy used (30 Gy).
Non-standard chemotherapy regime.
Burmeister,
2011, Australia3
75 patients with cT2e3 cN0e1
AC of the thoracic oesophagus
or gastro-oesophageal junction
CT (n ¼ 36)
CRT (n ¼ 39)
Unblinded, prospectively
randomised phase II
trial (II)
CT: 2 cycles cisplatin 80 mg/m2 þ 96 h
infusion of 5-FU
CRT: same dose of cisplatin, but
1000 mg/m2/d 5-FU in the 1st cycle and
800 mg/m2/d in the 2nd cycle
Concurrent with the 2nd cycle of CT 35
Gy of RT in 15 fractions over 3 w
OS: Median 29 months after CT and
32 months after CRT (p ¼ 0.83)
Toxicity: No difference
Path CR: 13% after CRT, 0% after CT
(p ¼ 0.02)
R0 resection: R1 rate was 0% after CRT
but 11% after CT (p ¼ 0.04)
Progression Free Survival: Median
14 months after CT and 26 months after
CRT (p ¼ 0.37)
Surgery was standardised.
Median follow-up 94 months (range
43e112 months).
Aimed for 100 patients, but recruitment
stopped after 75 patients as there were
problems with waiting list for RT.
Underpowered.
Swisher, 2010,
USA4
157 patients with cT1e3 cN0e1
AC or SCC of the oesophagus
entered into sequential trials
between 1990 and 2000
CT (n ¼ 76)
CRT (n ¼ 81)
Unblinded, prospectively
randomised phase II/III
trial (II)
CT (n ¼ 44) 3 cycles cisplatin
100 mg/m2 þ 5-FU 1000 mg/m2, (positive
response to CT: also given post-operative
Cisplatin þ 5-FU)
CT (n ¼ 32) 3e5 cycles of cisplatin
(3  30 mg/m2), 5-FU (3  1250 mg/m2) þ
arabinoside (2  1800 mg/m2) (if given
<5 cycles, remainder was given
post-operatively if evidence of response)
CRT: (n ¼ 38) 2 cycles of 5-FU, cisplatin þ
paclitaxel followed by a combination of
45 Gy of RT in 25 Gy fractions þ
Cisplatin þ 5-FU
CRT: (n ¼ 43) 2 cycles of CPT-11 þ
cisplatin, followed by 45 Gy of RT in 25 Gy
fractions þ Paclitaxel þ 5-FU
OS: Median survival 32 months for CRT vs.
18 months for CT (p ¼ 0.05)
5 year survival 36% for CRT, 21% for
CT (p ¼ 0.04)
Toxicity: Higher rates of neutropaenic
sepsis, nausea and vomiting, diarrhoea
and oesophagitis with CRT
Path CR: 29% vs. 3% for CRT vs. CT
(p < 0.01)
Signiﬁcant nodal downstaging: 77% vs.
35% for CRT vs. CT (p < 0.01)
Post-operative complications:
anastomotic leak e 7% in CRT group and
0% in CT group (p ¼ 0.03)
Atrial ﬁbrillation e CRT vs. CT 18% vs. 5%
(p ¼ 0.0012)
Pulmonary insufﬁciency e 15% vs. 3%
(p ¼ 0.007)
Hospital Mortality: CRT 7% vs. CT 4% p ¼ 0.4
CT trials took place between 1990 and
1995. Patients were recruited into
CRT trials between 1996 and 2000.
90% of CRT patients proceeded to
surgery vs. 75% in CT group (p ¼ 0.04).
Median follow-up 190 months for CT
and 93 months for CRT. Improvement
in survival with CRT seen even if
follow-up had ended in 2000
(p ¼ 0.005).
As a result of the number of trials,
there was wide heterogeneity in the
treatment patients received, and four
different regimens were used.
Morgan, 2007,
Wales5
205 patients with cT3, N0eN1
M0 AC or SCC of the oesophagus
between 1998 and 2005
CT: (n ¼ 88)
CRT: (n ¼ 117)
Non-randomised,
non-blinded cross-over
trial (III)
CT: either 2 cycles of cisplatin (80 mg/m2) þ
5-FU (1000 mg/m2), or epirubicin
(50 mg/m2), cisplatin (60 mg/m2) þ
5-FU (200 mg/m2)
CRT: 2 cycles of cisplatin (60 mg/m2) þ
5-FU (225 mg/m2 daily) followed by
45 Gy radiotherapy in 25 fractions þ
cisplatin þ 5-FU.
OS: Median survival 28 vs. 22 months for
CRT vs. CT
5 year survival 35% vs. 21% in the CRT vs.
CT groups (p ¼ 0.188) (on intention to treat
basis)
Toxicity: Grade IV neutropaenia 25% in CRT
group vs. 0% for CT group
Path CR: 18% vs. 3.4% in the CRT vs. CT
groups (p ¼ 0.012)
R0: 64.8% in CRT group
47.0% in CT group (p ¼ 0.009)
From 1998 patients received CRT,
then from 2002 onwards they received
CT. Of CRT patients, 91% were followed
up for 5 years. Of CT patients 59.8%
were followed up for 5 years.
24% of patients in the CRT group and
19% in the CT group did not progress
to surgery. However, 12% of patients
in the CT group had an open close
laparotomy vs. 5% in the CRT group.
(continued on next page)
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BEST EVIDENCE TOPICdirectly compared the results of neoadjuvant CT to CRT were
assessed in detail.
5. Search outcome
1115 papers were found using the described search technique
and abstracts were searched. Of these, 1110 papers did not address
the primary question and directly compare CRT to CT and therefore
were discarded. Five papers were identiﬁed that provided the best
evidence to answer the clinical question. These are presented in
Table 1.
6. Results
There were 2 randomised controlled trials (level II), 2 prospec-
tive series (level II) and a retrospective study (level III) which were
found to be directly relevant to the research question.
The ﬁrst RCT published by Stahl et al. in 2009 recruited 119
patients with locally advanced adenocarcinoma (T3eT4, NX, M0).3
The patients were recruited between 2000 and 2005 from 19
different hospitals in Germany. In the CTgroup, only 66% completed
the course, and one patient died of toxicity. Seventy-ﬁve percent of
patients completed CRT. The percentage of patients who proceeded
to surgery after neoadjuvant treatment was 88% and 82% in the CT
group and CRT groups, respectively. Complete pathological
response was signiﬁcantly higher in the CRT group (15%) compared
with CT group (2%) (p ¼ 0.03). The R0 resection rate was also
increased with CRT in those who had surgery, however given the
excess number of patients who did not proceed to surgery in the
CRT group there was no difference on an intention to treat analysis.
The improvement in 3-year survival data failed to reach signiﬁ-
cance (p ¼ 0.07). After the ﬁrst 125 patients were recruited, an
interim analysis revealed that another 163 patients would be
required for each arm to show an improvement in 3-year survival
by 10% (with 80% power) for the CRT arm. Therefore, less than a
third of the required number of patients had been recruited in the
ﬁrst 5 years, prompting early closure of the trial. Other criticisms of
this RCT include a low dose of radiotherapy (30 Gy) and the CT
regimen was prolonged with non-conventional schedule of in-
duction and concurrent treatment schedule.
The second RCT was published by Burmeister et al. in 2011.4 This
trial randomised 75 patients with adenocarcinoma of the thoracic
oesophagus or gastro-oesophageal junction with T2eT3, N0eN1,
M0 disease. There was no difference in toxicity due to neoadjuvant
therapy between the two arms. This study again showed an
improvement in the pathological response rate after CRT (13% vs.
0% in the CT group (p ¼ 0.02)) and there was a higher rate of R1
resection in the CT group (11% vs. 0% (p ¼ 0.04)). However, a higher
percentage of patients in the CT group proceeded to surgery (92%
vs. 85% in the CRT group). Therefore, there was no improvement in
R0 resection on an intention to treat basis. Five-year survival after
CRT was 45% vs. 36% for the CT group, but this was not statistically
signiﬁcant (p ¼ 0.6). Again, this trial was closed early due to poor
accruals and long waiting times for radiotherapy.
In 2010, Swisher et al. published a re-analysis of the outcomes of
157 patients that had been randomised to sequential phase II and
phase III studies of pre-operative CT or CRT.5 The data was collected
from a single centre, between 1990 and 2005. 85% of patients had
adenocarcinoma, and the majority had T2e3, N0e1, M0 disease.
There was a higher incidence of grade III and grade IV toxicity with
CRT compared to CT. In contrast to the two RCT previously dis-
cussed, there was a signiﬁcantly higher number of patients in the
CRT group who proceeded to surgery compared to the CT group
(90% vs. 75%, respectively (p ¼ 0.04)). There was no difference in
peri-operative mortality, but there was a higher incidence of post-
E. Hamilton et al. / International Journal of Surgery 12 (2014) 196e199 199
BEST EVIDENCE TOPICoperative morbidity in the CRT group. Again, there was improve-
ment in the pathological response rate after CRT (29% vs. 3% in the
CT group) and there was a signiﬁcant improvement in 5-year sur-
vival seen (36% of the CRT alive at 5 years vs. 21% of the CT group
calculated on an intention to treat basis (p¼ 0.04)). Major criticisms
of this research include that data from four different trials were
used in this analysis. In addition, the four trials were sequential and
spanned 10 years. Pre-treatment staging changed over this time
and the lack of endoscopic ultrasound and PET imaging earlier in
the study may have not excluded patients with advanced or met-
astatic disease. CT trials took place between 1990 and 1995. Pa-
tients were recruited into CRT trials between 1996 and 2000.
Furthermore, two different types of oesophagectomy were used.
However, it was an intention to treat analysis and did use high
quality data from randomised studies.
Morgan et al. performed a prospective cohort study of 205 pa-
tients with oesophageal cancer who underwent neoadjuvant
therapy followed by surgery.6 The ﬁrst cohort, from 1998 to 2002,
received CRT, whereas between 2002 and 2005 CT was used. The
patients were well staged with EUS, helical CT and staging lapa-
roscopy, but not PET scanning. The CRT patients were younger
compared to the CT group. Eighty three percent in the CT group had
adenocarcinoma compared with 70% in the CRT group. The com-
plete pathological response rate was higher after CRT (18% vs. 3.4%
in the CTgroup (p¼ 0.012)). The 5-year survival was not statistically
signiﬁcant (35% 5 year survival following CRT vs. 21% in the CT
group, p ¼ 0.188). However, 24% of patients in the CRT group and
19% in the CT group did not progress to surgery. Peri-operative
mortality was higher in the CRT group (10% vs. 1% for the CT
group (p ¼ 0.008)), but openeclose laparotomy was higher in the
CT group (12% vs. 5% in the CRT group, p ¼ 0.044).
Luu et al. performed a retrospective study published in 2008
involving 122 patients who underwent neoadjuvant treatment at a
single centre between 1995 and 2005 for stage II to stage IV dis-
ease.7 Seventy six percent of the CT group had adenocarcinoma
compared with 81% in the CRT group. Ninety seven percent of the
patients in both groups completed all planned neoadjuvant treat-
ment and proceeded to surgery. Peri-operative complications were
higher in the CRT group with four peri-operative deaths and an
overall complication rate of 48% compared to 33% overall compli-
cation rate in the CT group (p ¼ 0.09). Consistent with the other
studies, there was improvement in the pathological complete
response rate after CRT (17% vs. 3% in the CT group (p ¼ 0.02)). The
5-year survival after CRT was 41% vs. 31% for the CT group, but this
result did not reach statistical signiﬁcance. The main criticisms of
this study were that it was retrospective and the pre-treatment
stage was not accurately known. Survival was calculated from the
date of oesophagectomy and not the date of commencing neo-
adjuvant therapy.7. Clinical bottom line
The current literature comparing neoadjuvant CRT vs. CT prior
to oesophagectomy for cancer is limited, in particular the rando-
mised trials which were underpowered and closed early. The
studies presented here suggest that CRT increases the pathological
complete response rate and may be associated with a survival
advantage. However, this is at the cost of increased peri-operative
morbidity and mortality that may offset the survival gain. Two high
quality randomised controlled trials have recently started recruit-
ing and are comparing different neoadjuvant CT and CRT regimens
(MAGIC vs. CROSS [NCT01726452, ClinicalTrials.gov] and Neo-
scope8) and should clarify the existing deﬁcits in the literature.
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